Table 3A.

Laboratory findings in 23 patients with reported MAS for platelet count.

Group	Patient No.	Event No.	PLT, × 10 ⁴/µl				Outcome of MAS
Group	Patient No.	Event No.	Baseline Value	At Time of MAS Onset	Worst Value During MAS	At Time of Outcome	Outcome of MAS
1	1	1	37.3	12.7	6.2	23.8	Recovered
	2^a	2	40.6	23.1	4.1	40.6^e	Recovered
	3	3	21.6	11.9	11.9	25.1^e	Recovered
2	3	4	21.6	8.3	3.3	29.5	Recovered
	4	5	24.1	10.9	10.9	39	Recovered
	5	6	14.4	9.4	9.4	45	Recovered
		7	14.4	14.4	11.4	27.5	Recovered
	6	8	27.7	39	3	32.3	Recovered
	7	9	76.9	—	18.3	42.6^e	Recovered
	8	10	20.1	10	10	29.6	Recovered
	9^b	11	40.6	13	9.6	26.8	Recovered
	10	12	13.1	8.5	3.9	15.5	Recovered
	11	13	20.1	17.5	16	24.9	Recovered
	12	14	21.2	14.4	14.4	26.6	Recovered
	13	15	69.3	18.2	0.2	7.1	Not recovered
3	14	16	32.2	4.6^d	4.3	25.5	Recovered
3	15^c	17	31	14	3.7	29.1	Improved
Median			24.1	12.9	9.4	27.5
Range			13.1–76.9	4.6–39	0.2–18.3	7.1–45
4	16	18	31.5	7.1^d	7.1	20.7	Recovered
	17	19	37.6	26.1	24.8	36.2	Not recovered
	18	20	35.7	10.5^d	5.9	41^e	Improved
	19	21	12.7	19	13.4	15.8	Recovered
	20	22	25.1	13.9	12.7	24.2	Recovered
	21	23	74.9	14.6	1.7	—	Unknown
	22	24	25.8	—	2.7	—	Recovered
	23	25	—	—	—	—	Unknown

Baseline value: Value at start of TCZ administration in the all-patient registry surveillance.
↵a, b, c Representative examples of Group 1 (definitive MAS), Group 2 (probable MAS), and Group 3 (EB-VAHS), respectively.
↵d ± 1 day from onset.
↵e ± 3 days from outcome.